Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences Inc
(NQ:
CSTL
)
22.92
+0.24 (+1.06%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Castle Biosciences Inc
< Previous
1
2
3
4
5
6
7
8
Next >
Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day
September 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association
September 13, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Participate in Upcoming Investor Conferences
September 01, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Host Investor Day on Sept. 20, 2022
August 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Reports Second Quarter 2022 Results
August 08, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus
August 04, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8
July 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma
July 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma
July 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Honored with a 2022 Arizona Top Workplace Award
July 18, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative
June 23, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022
June 22, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Support for OHSU’s War on Melanoma™
June 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma
June 14, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at the JMP Securities Life Sciences Conference
June 08, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
May 27, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
May 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
May 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
May 20, 2022
From
Castle Biosciences
Via
Business Wire
Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
May 19, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
May 10, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Reports First Quarter 2022 Results
May 09, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
May 06, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives
May 03, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
April 29, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer
April 27, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Completes Acquisition of AltheaDx
April 26, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9
April 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients
April 21, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.